Cardiopulmonary function as related to thromboxane A2 synthesis in experimental septic shock.
The aim of the present study was to explore the possible involvement of thromboxane A2(TxA2) in the development of cardiopulmonary dysfunction in experimental septic shock. Sepsis was induced in anesthetized cats by intravenous (i.v.) infusion of live Escherichia coli. One series (No. = 12) was pretreated with a specific TxA2 synthetase inhibitor, dazmegrel; another (No. = 8) served as a septic control series. In both series a systemic arterial hypotension developed after 2 hr; no differences in cardiac function were detected. After 2 hr bacteremia cardiac preload was increased by a rapid infusion of dextran. This showed that cardiac function was significantly more preserved in dazmegrel-pretreated cats compared with septic controls. Pretreatment with dazmegrel totally prevented the pulmonary vascular response to bacterial infusion. The pulmonary compliance decreased to 40% in controls but to only 75% in the dazmegrel series, and airway resistance increased to 300% and 140%, respectively. The ventilation-perfusion ratio was less impaired in the pretreated series. Pretreatment with dazmegrel abolished the increase in thromboxane B2 (TxB2), the stable metabolite of TxA2, seen in the untreated series. The rise in 6-keto-prostaglandin F1a (6-keto-PGF1a), the stable metabolite of prostaglandin I2PGI2, was evident in both series. We concluded that TxA2 is important for the impaired cardiac performance in septic shock. Furthermore, TxA2 is involved, but not as the only factor, in the development of pulmonary dysfunction.
Schützer
K M
KM
Department of Lung Medicine, Renström's Hospital, Göteborg, Sweden.
Lindholm
E
E
Haglund
U
U
Falk
A
A
D000403:Airway Resistance; D000818:Animals; D002415:Cats; D004926:Escherichia coli; D006321:Heart / Q000503:physiopathology*; D006439:Hemodynamics; D007093:Imidazoles / Q000494:pharmacology; D008168:Lung / Q000503:physiopathology*; D008170:Lung Compliance; D012772:Shock, Septic / Q000097:blood / Q000209:etiology / Q000503:physiopathology*; D013928:Thromboxane A2 / Q000096:biosynthesis*; D013929:Thromboxane B2 / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors; D014692:Ventilation-Perfusion Ratio
D007093:Imidazoles; C039242:dazmegrel; D013929:Thromboxane B2; D013928:Thromboxane A2; D013930:Thromboxane-A Synthase